Gene

MET

MET proto-oncogene, receptor tyrosine kinase

Explore in graph →CI-GENE-00012412HGNC:7029 ENSG00000105976 NCBI 4233 CIViC Cancer geneApproved

Curated evidence

Clinical evidence (140)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 101–140 of 140 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
CD274 Overexpression + MET Exon 14 Skipping MutationCD274 MET6
Pembrolizumab	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive

Cohorts

Alteration frequency by cohort (132)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved132 cohort rows (showing 50, sorted by frequency) · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Colorectal Cancer (MSK, Cancer Discovery 2022) coadread_mskresistance_2022	Colorectal Adenocarcinoma	Ssm

Literature

Linked publications (30)

25 per page, newest first.

pubmedPublishedShowing 1–25 of 30 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer.
· N Engl J Med · 2020 · PMID 32877583 · validated civic_curation pubmed
Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial.
· Lancet Oncol · 2017 · PMID 28958504 · validated civic_curation pubmed
Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance.
· Cell · 2015 · PMID 26359985 · validated civic_curation pubmed
Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma.
· J Clin Oncol · 2013 · PMID 23213094 · validated

MET D1228N + MET Exon 14 Skipping Mutation2
Crizotinib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	C	Supports Resistance	2	submitted	EID11403 An 83-year old male (smoker) was diagnosed with adenocarcinoma of right upper lung. Next-generation sequencing (NGS) analysis found MET exon 14 skipping mutation and MET C526F mutation and the patient… (full text at CIViC) PMID 31055074 · Jin et al., 2019 · Open in CIViC	civic
〃	Lung Adenocarcinoma	Predictive	C	Supports Resistance	2	submitted	EID11413 A 70-year old male (former smoker: 50 pack-years) was diagnosed with stage Ib lung adenocarcinoma. Next-generation sequencing showed a MET exon 14 skipping mutation, confirmed later with RNA analysis.… (full text at CIViC) PMID 34994615 · Pruis et al., 2021 · Open in CIViC	civic

MET Exon 14 Skipping Mutation + MET Overexpression2
Crizotinib	Lung Sarcomatoid Carcinoma	Predictive	C	Supports Sensitivity Response	2	submitted	EID11382 A 61-year old male (non-smoker) was diagnosed with sarcomatoid non-small-cell lung cancer (CK+, TTF1+, and vimentin+). Genomic profiling showed two MET alterations that showed exon 14 skipping mutatio… (full text at CIViC) PMID 26709483 · Lee et al., 2015 · Open in CIViC	civic
AXL Receptor Tyrosine Kinase/cMET Inhibitor BPI-9016M	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Does Not Support Sensitivity Response	3	submitted	EID11422 38 patients with locally advanced or metastatic non-small-cell lung cancer were divided into two groups, Part A had c-MET overexpression and Part B had MET exon 14 skipping mutation. Part A was given … (full text at CIViC) PMID 37041472 · Hu et al., 2023 · Open in CIViC	civic

MET Overexpression9
(diagnostic)	Lung Non-Small Cell CarcinomaCURATED_BROADER	Diagnostic	B	Supports Positive	4	submitted	EID11371 Analysis of 32 patients with lung neoplasms from the University of Chicago Medical Center. Results yielded high c-MET levels in 100% of all non-small-cell lung cancer samples (n=23) and 89% of all cel… (full text at CIViC) PMID 15735036 · Ma et al., 2005 · Open in CIViC	civic
Cabozantinib	Ovarian Clear Cell CarcinomaUNRESOLVED	Predictive	D	Supports Sensitivity Response	3	submitted	EID7932 Transcriptome sequencing found ovarian clear cell carcinoma (CCC) tissue has 2.2-fold increased expression of MET compared to high-grade serous carcinoma (HGSC) cells. The effects of cabozantinib wer… (full text at CIViC) PMID 29061793 · Nakatani et al., 2017 · Open in CIViC	civic
Crizotinib	Uveal Melanoma	Predictive	D	Supports Sensitivity Response	1	accepted	EID1583 c-MET and ligand HGF were expressed by 6 uveal melanoma cell lines in-vitro. GNA-mutant cell lines (n=3) showed stronger expression of ligand and receptor as well as more receptor phosphorylation. SiR… (full text at CIViC) PMID 24140933 · Surriga et al., 2013 · Open in CIViC	civic
〃	Uveal Melanoma	Predictive	E	Supports Sensitivity Response	2	rejected	EID1582 Preclinical study in uveal melanoma cell lines. c-MET was identified as a transcriptional target of miR-144. miR-144 was downregulated in 4 uveal melanoma cell lines and 5 human uveal melanoma tumor t… (full text at CIViC) PMID 25961751 · Sun et al., 2015 · Open in CIViC	civic
C-Met Inhibitor + ERBB3 Inhibitor + Mitogen-Activated Protein Kinase Kinase InhibitorCombination	Uveal Melanoma	Predictive	D	Supports Sensitivity Response	3	submitted	EID3037 MEK inhibitors improve survival in cutaneous melanoma patients but show only modest efficacy in metastatic uveal melanoma patients. In this study, we screened for growth factors that elicited resistan… (full text at CIViC) PMID 25952648 · Cheng et al., 2015 · Open in CIViC	civic
Rilotumumab	Gastric Adenocarcinoma	Predictive	B	Does Not Support Sensitivity Response	5	accepted	EID5835 In this randomised, double-blind, placebo-controlled phase 3 trial, 609 patients with MET+ (expression of at least 1+ intensity on 25% or more tumor cells) gastric cancer or gastroesophageal adenocarc… (full text at CIViC) PMID 28958504 · Catenacci et al., 2017 · Open in CIViC	civic
Selumetinib + TrametinibSubstitutes	Uveal Melanoma	Predictive	D	Supports Resistance	3	accepted	EID3038 In this study the authors screened for growth factors that elicited resistance in newly characterized metastatic uveal melanoma cell lines to clinical-grade MEK inhibitors, trametinib and selumetinib,… (full text at CIViC) PMID 25952648 · Cheng et al., 2015 · Open in CIViC	civic
Vemurafenib	Cutaneous MelanomaALIAS	Predictive	B	Supports Resistance	4	accepted	EID1581 Whole exome sequencing, transcriptome and methylome alterations in 48 melanoma samples with acquired resistance to BRAFi +/- MEKi therapy compared to patient-matched baseline melanoma tissues were ana… (full text at CIViC) PMID 26359985 · Hugo et al., 2015 · Open in CIViC	civic
〃	Cutaneous MelanomaALIAS	Predictive	B	Does Not Support Resistance	3	accepted	EID1584 FFPE tumours from patients enrolled in the BRIM2 (n = 59) and BRIM3 (n = 150) trials of vemurafenib in advanced BRAF mutant (V600E/K) melanoma were analyzed for MET expression (IHC). Pretreatment MET … (full text at CIViC) PMID 23802768 · Jubb et al., 2013 · Open in CIViC	civic

MET Amplification + MET Exon 14 Skipping Mutation2
(prognostic)	Malignant Gastric Neoplasm	Prognostic	C	Supports Poor Outcome	3	submitted	EID11381 A 27-year old male patient displayed poorly differentiated gastric adenocarcinoma and massive malignant ascites. Shortly after his diagnosis, the patient died. After genomic sequencing, it was shown t… (full text at CIViC) PMID 26375439 · Lee et al., 2015 · Open in CIViC	civic
Cabozantinib + CrizotinibSequential	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	C	Supports Sensitivity Response	2	submitted	EID11390 A 65-year old white male (non-smoker) developed recurrent metastatic NSCLC 17 months after lobectomy for stage IA disease. Genomic profiling showed MET exon 14 skipping mutation without MET amplificat… (full text at CIViC) PMID 27693535 · Klempner et al., 2017 · Open in CIViC	civic